Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Nienke M Nota"'
Autor:
Moya H Schutte, Robert Kleemann, Nienke M Nota, Chantal M Wiepjes, Jessica M Snabel, Guy T'Sjoen, Abel Thijs, Martin den Heijer
Publikováno v:
PLoS ONE, Vol 17, Iss 3, p e0261312 (2022)
BackgroundCardiovascular risk is increased in transgender persons using gender-affirming hormone therapy. To gain insight into the mechanism by which sex hormones affect cardiovascular risk in transgender persons, we investigated the effect of hormon
Externí odkaz:
https://doaj.org/article/969b45d14b0f45f1a5e72909bb3e4677
Autor:
Evelien T M Boekhout-Berends, Chantal M Wiepjes, Nienke M Nota, Hans H M Schotman, Annemieke C Heijboer, Martin den Heijer
Publikováno v:
European Journal of Endocrinology. 188:457-466
Objective Interpreting laboratory results for transgender individuals who started hormone therapy requires careful consideration, specifically for analytes that have sex-specific reference intervals. In literature, conflicting data exist on the effec
Autor:
Epie Boven, Harm van Tinteren, Aafke H. Honkoop, Johanneke E.A. Portielje, Ankie M.T. van der Velden, Joan van den Bosch, Monique M.E.M. Bos, Agnes Jager, Nienke M. Nota, Siu W. Lam
Purpose: We examined whether pretreatment levels of angiogenesis- or hypoxia-related proteins and their changes after one cycle of first-line bevacizumab-based therapy were associated with response, PFS, or OS in patients with metastatic breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ba4f07774af27b81ffc97bcaf6441ec
https://doi.org/10.1158/1078-0432.c.6524210.v1
https://doi.org/10.1158/1078-0432.c.6524210.v1
Autor:
Epie Boven, Harm van Tinteren, Aafke H. Honkoop, Johanneke E.A. Portielje, Ankie M.T. van der Velden, Joan van den Bosch, Monique M.E.M. Bos, Agnes Jager, Nienke M. Nota, Siu W. Lam
Supplementary Table 1. Clinical outcome of original trial population and biomarker population Supplementary Table 2. Baseline plasma protein levels vs baseline patient and tumor characteristics Supplementary Table 3. Spearman Rho correlation coeffici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92209ee6113aed3e189e26a6148dad36
https://doi.org/10.1158/1078-0432.22459391
https://doi.org/10.1158/1078-0432.22459391
Autor:
Nienke M Nota, Matthijs Westerman
Publikováno v:
British journal of haematology. 196(4)
Autor:
Nienke M. Nota, Baudewijntje P. C. Kreukels, Christel J. M. de Blok, Annemieke Staphorsius, Daan M. van Velzen, Martin den Heijer, Chantal M. Wiepjes, Louis J. G. Gooren
Publikováno v:
The Lancet Diabetes and Endocrinology, 9(10), 663-670. Elsevier BV
de Blok, C J M, Wiepjes, C M, van Velzen, D M, Staphorsius, A S, Nota, N M, Gooren, L J G, Kreukels, B P C & den Heijer, M 2021, ' Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria ', The Lancet Diabetes and Endocrinology, vol. 9, no. 10, pp. 663-670 . https://doi.org/10.1016/S2213-8587(21)00185-6
de Blok, C J M, Wiepjes, C M, van Velzen, D M, Staphorsius, A S, Nota, N M, Gooren, L J G, Kreukels, B P C & den Heijer, M 2021, ' Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria ', The Lancet Diabetes and Endocrinology, vol. 9, no. 10, pp. 663-670 . https://doi.org/10.1016/S2213-8587(21)00185-6
Summary Background Increased mortality in transgender people has been described in earlier studies. Whether this increased mortality is still present over the past decades is unknown. Therefore, we aimed to investigate trends in mortality over five d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9351b5f505de965acb9c093cb77c67cd
https://research.vumc.nl/en/publications/61e96901-24cc-4594-878b-476e740b3420
https://research.vumc.nl/en/publications/61e96901-24cc-4594-878b-476e740b3420
The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis
Autor:
Moya H. Schutte, Robert Kleemann, Nienke M. Nota, Chantal M. Wiepjes, Jessica M. Snabel, Guy T’Sjoen, Abel Thijs, Martin den Heijer
Publikováno v:
PLOS ONE
PLoS ONE, 17(3 March):e0261312. Public Library of Science
Schutte, M H, Kleemann, R, Nota, N M, Wiepjes, C M, Snabel, J M, t'Sjoen, G, Thijs, A & Heijer, M D 2022, ' The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis ', PLoS ONE, vol. 17, no. 3 March, e0261312 . https://doi.org/10.1371/journal.pone.0261312
PLoS ONE, 17(3 March):e0261312. Public Library of Science
Schutte, M H, Kleemann, R, Nota, N M, Wiepjes, C M, Snabel, J M, t'Sjoen, G, Thijs, A & Heijer, M D 2022, ' The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis ', PLoS ONE, vol. 17, no. 3 March, e0261312 . https://doi.org/10.1371/journal.pone.0261312
Background Cardiovascular risk is increased in transgender persons using gender-affirming hormone therapy. To gain insight into the mechanism by which sex hormones affect cardiovascular risk in transgender persons, we investigated the effect of hormo
Autor:
G. Kees Hovingh, Alessia Paldino, Justine Defreyne, Martin den Heijer, Maartje Klaver, S. Simsek, Nienke M. Nota, Guy T'Sjoen, Daan M. van Velzen, Abel Thijs
Publikováno v:
Van Velzen, D M, Paldino, A, Klaver, M, Nota, N M, Defreyne, J, Kees Hovingh, G, Thijs, A, Simsek, S, Sjoen, G T & Den Heijer, M 2019, ' Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen ', Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 6, pp. 1937-1947 . https://doi.org/10.1210/jc.2018-02138
Journal of Clinical Endocrinology and Metabolism, 104(6), 1937-1947. The Endocrine Society
Journal of clinical endocrinology and metabolism, 104(6), 1937-1947. The Endocrine Society
Journal of Clinical Endocrinology and Metabolism, 104(6), 1937-1947. The Endocrine Society
Journal of clinical endocrinology and metabolism, 104(6), 1937-1947. The Endocrine Society
Context: The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective: The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM
Autor:
Jeske J. K. van Diemen, Luuk J. J. Scheres, Martin den Heijer, Nienke M Nota, Nienke L. D. Selier, Suzanne C. Cannegieter
Publikováno v:
Journal of Thrombosis and Haemostasis, 19(4), 1029-1037. WILEY
Journal of Thrombosis and Haemostasis, 19(4), 1029-1037. Wiley-Blackwell
Scheres, L J J, Selier, N L D, Nota, N M, van Diemen, J J K, Cannegieter, S C & den Heijer, M 2021, ' Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen ', Journal of Thrombosis and Haemostasis, vol. 19, no. 4, pp. 1029-1037 . https://doi.org/10.1111/jth.15256
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 19(4), 1029-1037. Wiley-Blackwell
Scheres, L J J, Selier, N L D, Nota, N M, van Diemen, J J K, Cannegieter, S C & den Heijer, M 2021, ' Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen ', Journal of Thrombosis and Haemostasis, vol. 19, no. 4, pp. 1029-1037 . https://doi.org/10.1111/jth.15256
Journal of Thrombosis and Haemostasis
Background The transgender population that uses gender‐affirming hormone therapy (GAHT) is rapidly growing. The (side) effects of GAHT are largely unknown. We examined the effect of GAHT on coagulation parameters associated with venous thromboembol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b7c1513c5f8f0837de6df77efdf5b4b
http://hdl.handle.net/1887/3276186
http://hdl.handle.net/1887/3276186
Autor:
Nienke M. Nota, Daniël H. van Raalte, S. Simsek, Daan M. van Velzen, Renée de Mutsert, Chantal M. Wiepjes, Martin den Heijer
Publikováno v:
SSRN Electronic Journal.
Background: In trans women receiving hormone therapy, body fat and insulin resistance increases, with opposite effects in trans men. These metabolic alterations may increase or decrease the risk of developing type 2 diabetes in trans women and trans